Sarepta Therapeutics Inc (SRPT): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Sarepta Therapeutics ( SRPT) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.5%. By the end of trading, Sarepta Therapeutics fell $0.85 (-2.3%) to $36.36 on average volume. Throughout the day, 1,590,519 shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 1,688,700 shares. The stock ranged in price between $36.08-$38.54 after having opened the day at $37.60 as compared to the previous trading day's close of $37.21. Other companies within the Health Care sector that declined today were: Transcept Pharmaceuticals ( TSPT), down 12.2%, Neostem ( NBS), down 10.6%, Progenics Pharmaceuticals ( PGNX), down 9.9% and Imprimis Pharmaceuticals ( IMMY), down 9.8%.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Sarepta Therapeutics has a market cap of $1.2 billion and is part of the drugs industry. Shares are up 42.3% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Sarepta Therapeutics as a sell. Among the areas we feel are negative, one of the most important has been the company's poor growth in earnings per share.

On the positive front, Omeros Corporation ( OMER), up 68.2%, GW Pharmaceuticals PLC ADR ( GWPH), up 56.7%, Mirati Therapeutics ( MRTX), up 37.1% and NovaBay Pharmaceuticals ( NBY), up 24.6% , were all gainers within the health care sector with AstraZeneca ( AZN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Sarepta Therapeutics Chart Patterns Look Good

Verastem Shares Are Exploding 50% -- Here's Why

Watch the Key Technical Levels

Net Seller, but Itching to Put More Cash to Work